Company
Aligos Therapeutics
Utilizing the expertise of our medicinal chemistry and biology teams, we target liver and viral diseases with a need for better efficacy.
Also known as Aligos Therapeutics, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- South San Francisco, CA, United States
- Legal name
- Aligos Therapeutics, Inc.
- aligos.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
We have purpose-built drugs with enhanced pharmacologic properties for large unmet medical needs in liver and viral diseases where better therapies will greatly impact patients.
Funding snapshot
- Total raised
- $282MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $105M2025-02-11
Funding rounds
- Round, 2025
- $105M2025-02-11, SEC form D sold, 12 investors
- Round, 2023
- $92.2M2023-10-25, SEC form D sold, 11 investors
- Round, 2019
- $85M2019-12-23, SEC form D sold, 38 investors
Products
- Other
- ALG-170675
- Other
- Pevifoscorvir sodium
Loading relationship preview